Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37000626)

  • 1. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
    Mertens S; Huismans MA; Verissimo CS; Ponsioen B; Overmeer R; Proost N; van Tellingen O; van de Ven M; Begthel H; Boj SF; Clevers H; Roodhart JML; Bos JL; Snippert HJG
    Cell Rep; 2023 Apr; 42(4):112324. PubMed ID: 37000626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids.
    Fujino S; Miyoshi N; Ito A; Yasui M; Ohue M; Ogino T; Takahashi H; Uemura M; Matsuda C; Mizushima T; Doki Y; Eguchi H
    Mol Cancer Res; 2021 May; 19(5):812-822. PubMed ID: 33579816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.
    Verissimo CS; Overmeer RM; Ponsioen B; Drost J; Mertens S; Verlaan-Klink I; Gerwen BV; van der Ven M; Wetering MV; Egan DA; Bernards R; Clevers H; Bos JL; Snippert HJ
    Elife; 2016 Nov; 5():. PubMed ID: 27845624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling.
    Ponsioen B; Post JB; Buissant des Amorie JR; Laskaris D; van Ineveld RL; Kersten S; Bertotti A; Sassi F; Sipieter F; Cappe B; Mertens S; Verlaan-Klink I; Boj SF; Vries RGJ; Rehmann H; Vandenabeele P; Riquet FB; Trusolino L; Bos JL; Snippert HJG
    Nat Cell Biol; 2021 Apr; 23(4):377-390. PubMed ID: 33795873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient.
    Osumi H; Muroi A; Sakahara M; Kawachi H; Okamoto T; Natsume Y; Yamanaka H; Takano H; Kusama D; Shinozaki E; Ooki A; Yamaguchi K; Ueno M; Takeuchi K; Noda T; Nagayama S; Koshikawa N; Yao R
    Sci Rep; 2020 Oct; 10(1):17455. PubMed ID: 33060766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
    Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
    Alem D; Yang X; Beato F; Sarcar B; Tassielli AF; Dai R; Hogenson TL; Park MA; Jiang K; Cai J; Yuan Y; Fernandez-Zapico ME; Tan AC; Fleming JB; Xie H
    Mol Carcinog; 2023 Jul; 62(7):1025-1037. PubMed ID: 37042566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of SOS1 Inhibitor-Based Degraders to Target
    Bian Y; Alem D; Beato F; Hogenson TL; Yang X; Jiang K; Cai J; Ma WW; Fernandez-Zapico M; Tan AC; Lawrence NJ; Fleming JB; Yuan Y; Xie H
    J Med Chem; 2022 Dec; 65(24):16432-16450. PubMed ID: 36459180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
    Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.